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OBJECTIVE — Gestational impaired glucose tolerance (GIGT), deﬁned by a single abnormal
value on antepartum 3-h oral glucose tolerance test (OGTT), is a metabolically heterogeneous
disorder. Indeed, the antepartum metabolic phenotype of women with a single abnormal value
at 1 h during the OGTT (1-h GIGT) resembles that of women with gestational diabetes mellitus
(GDM), whereas GIGT at 2 or 3 h (2/3-h GIGT) is similar to normal glucose tolerance (NGT).
Thus, we hypothesized that 1-h GIGT would be associated with the same adverse outcomes as
GDM, i.e., increased infant birth weight and postpartum metabolic dysfunction.
RESEARCH DESIGN AND METHODS — A total of 361 women underwent an ante-
partum glucose challenge test (GCT) and a 3-h OGTT, assessment of obstetrical outcome at
delivery, and metabolic characterization by OGTT at 3 months postpartum. The antepartum
GCT/OGTT identiﬁed ﬁve study groups: GDM (n  97), 1-h GIGT (n  28), 2/3-h GIGT (n 
34),abnormalGCTNGT(abnormalGCTwithNGTonOGTT)(n128),andnormalGCTNGT
(normal GCT with NGT on OGTT) (n  74).
RESULTS — Caesariansectionratewashigherinwomenwith1-hGIGT,butbirthweightdid
not differ signiﬁcantly between the non-GDM groups (P  0.1978). At 3 months postpartum,
glycemia (area under the glucose curve) progressively increased across the groups from normal
GCTNGTtoabnormalGCTNGTto2/3-hGIGTto1-hGIGTtoGDM(P0.0001),whileboth
insulin sensitivity (ISOGTT) and -cell function (insulinogenic index/homeostasis model assess-
ment of insulin resistance [HOMA-IR]) progressively decreased (P  0.002 and P  0.0001,
respectively). The strongest independent negative predictors of insulinogenic index/HOMA-IR
were GDM (t  4.1, P  0.0001) and 1-h GIGT (t  3.8, P  0.0002).
CONCLUSIONS — Like GDM, 1-h GIGT is associated with postpartum glycemia, insulin
resistance, and -cell dysfunction.
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G
estational diabetes mellitus (GDM)
is associated with signiﬁcant short-
and long-term consequences (1,2).
In the short term, the most pressing con-
cernisanincreasedriskofadverseobstet-
rical outcomes related to fetal overgrowth
and increased birth weight (1,3). The
long-term concern is that women with a
history of GDM have chronic insulin re-
sistance and underlying -cell dysfunc-
tion, leading to a substantially elevated
risk of developing type 2 diabetes in the
years following the index pregnancy
(2,4). Thus, given these potential conse-
quences, pregnant women are commonly
screened for GDM by oral glucose toler-
ance test (OGTT) in late 2nd trimester,
whereupon affected women are treated
with glucose-lowering therapy (diet, in-
sulin)toimproveobstetricaloutcomeand
advised to undergo testing for type 2 dia-
betes in the postpartum (3,5).
WhereasGDM(diagnosedbytwoab-
normal glucose values on 3-h OGTT in
pregnancy) leads to these interventions,
gestational impaired glucose tolerance
(GIGT)(deﬁnedbyasingleabnormalglu-
cose value on the OGTT) generally does
not precipitate any speciﬁc treatment rec-
ommendations. Traditionally, it has been
felt that GIGT represents an intermediate
phenotypebetweennormalglucosetoler-
ance (NGT) and GDM (6,7). Interest-
ingly, however, it has recently emerged
that GIGT is actually a heterogeneous
metabolic disorder, as deﬁned by the gly-
cemic response on the OGTT (8). Specif-
ically, the metabolic phenotype in
pregnancy of women with a single abnor-
malglucosevalueat1hduringtheOGTT
(1-h GIGT) resembles that of GDM, as
both conditions are characterized by in-
creasedseverityofglycemia,insulinresis-
tance, and decreased circulating
adiponectin. In contrast, GIGT at 2 or 3 h
during the OGTT (2/3-h GIGT) is more
similar to NGT (8). In light of these data,
we hypothesized that 1-h GIGT may be
associated with the same adverse out-
comes as GDM, namely, 1) increased in-
fant birth weight and 2) postpartum
hyperglycemia, insulin resistance, and
-cell dysfunction. Thus, our objective in
the current study was to systematically
evaluate obstetrical outcomes and post-
partum metabolic function in a well-
characterized cohort of women stratiﬁed
by glucose tolerance status in pregnancy,
ranging from NGT to 2/3-h GIGT to 1-h
GIGT to GDM.
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METHODS— This analysis was con-
ducted in the setting of an ongoing obser-
vational study of early events in the
natural history of type 2 diabetes, in
which a cohort of women recruited at the
time of antepartum GDM screening is
undergoing longitudinal metabolic
characterization in pregnancy and the
postpartum period. Standard obstetri-
cal practice at our institution involves
universalscreeningforGDMinallpreg-
nant women at 24–28 weeks’ gestation
by 50-g glucose challenge test (GCT)
followed by, if the GCT is abnormal,
referral for a diagnostic OGTT. In the
study, healthy pregnant women are re-
cruited in late 2nd trimester, either be-
fore or just after their GCT. Regardless
of the GCT result, all study participants
then undergo a 3-h 100-g OGTT for de-
termination of glucose tolerance status
in pregnancy. At 3 months postpartum,
participants undergo reassessment by
2-h75-gOGTT.Thestudyprotocolwas
approved by the Mount Sinai Hospital
Research Ethics Board, and all partici-
pants provided written informed con-
sent. The current analysis was restricted
to the Caucasian women with singleton
pregnancies who have completed the
3-month postpartum OGTT to date
(n  361).
Baseline evaluation
On the morning of the OGTT in preg-
nancy, data regarding medical, obstetri-
cal, and family history were collected by
interviewer-administered questionnaire.
Anthropometric measurements of height
andweightwereobtainedusingamedical
scale. Based on the GCT and OGTT, par-
ticipantswerestratiﬁedintothefollowing
ﬁve baseline glucose tolerance groups:
1. GDM, deﬁned by National Diabetes
Data Group (NDDG) criteria (9),
which requires at least two of the fol-
lowing on the OGTT: fasting glucose
5.8 mmol/l, 1-h glucose 10.6
mmol/l, 2-h glucose 9.2 mmol/l, or
3-h glucose 8.1 mmol/l
2. 1-hGIGT,deﬁnedbymeetingonlythe
1-h criterion above
3. 2/3-hGIGT,deﬁnedbymeetingeither
only the 2-h criterion or only the 3-h
criterion
4. Abnormal GCT NGT, deﬁned as hav-
ing an abnormal 50-g GCT (1-h post-
challenge plasma glucose 7.8
mmol/l) followed by NGT on the
OGTT(deﬁnedbymeetingnoneofthe
NDDG criteria)
5. NormalGCTNGT,deﬁnedashavinga
normal GCT followed by NGT on the
OGTT
There was also one woman with
GIGT based on her fasting glucose value.
Because isolated fasting hyperglycemia is
likely metabolically very different from
postload GIGT, this individual was ex-
cluded from the current analysis.
Obstetrical outcomes
Data on obstetrical outcome were ob-
tained from a database that tracks labor
and delivery data at Mount Sinai Hospital
(Ontario,Canada).Largeforgestationage
(LGA) was deﬁned as sex-speciﬁc birth
weight for gestational age above the 90th
percentile of Canadian population fetal
growth curves (10). Macrosomia was de-
ﬁned as birth weight 4,000 g.
Postpartum evaluation
At 3 months postpartum, participants re-
turned for a 2-h 75-g OGTT. Interviewer-
administered questionnaires were
completed,andphysicalexaminationwas
performed including measurements of
blood pressure (measured twice 5 min
apart by automatic sphygmomanometer)
(Dinamap Pro 100–400), weight, and
waist circumference.
Laboratory measurements and
physiologic indexes
All OGTTs were performed in the morn-
ing after overnight fast. Venous blood
samples were drawn for measurement of
glucose and insulin at fasting and at 30,
60, and 120 min (and 180 min in preg-
nancy).Speciﬁcinsulinwasmeasuredus-
ingtheRocheElecsys1010immunoassay
analyzer and the electrochemilumines-
cence immunoassay kit. This assay shows
0.05% cross-reactivity to intact human
proinsulin and the primary circulating
split form (Des 31,32).
At both baseline and follow-up, gly-
cemia was assessed by the area under the
glucose curve (AUCgluc) during the
OGTT, calculated using the trapezoidal
rule. Insulin sensitivity was measured us-
ing the insulin sensitivity index (ISOGTT)
of Matsuda and DeFronzo (11). In preg-
nant women, ISOGTT exhibits better cor-
relation with insulin sensitivity measured
by euglycemic-hyperinsulinemic clamp
than either homeostasis model assess-
ment of insulin resistance (HOMA-IR) or
quantitative insulin sensitivity check in-
dex (12). -Cell function was assessed by
the insulinogenic index divided by
HOMA-IR (13,14). The insulinogenic in-
dex was calculated as the incremental
change in insulin concentration during
the ﬁrst 30 min of the OGTT divided by
the incremental change in glucose during
thesametimeperiod(15).HOMA-IRwas
calculated as previously described (16).
Statistical analyses
All analyses were conducted using the
SAS 9.1 (SAS Institute, Cary, NC). Con-
tinuous variables were tested for normal-
ity of distribution, and natural log
transformations of skewed variables were
used, where necessary, in subsequent
analyses.InTables1and2,foreachstudy
group, continuous variables are pre-
sented as median followed by interquar-
tile range if skewed or mean  SD if
normally distributed, while categorical
variables are presented as proportions.
Univariate differences across the groups
in pregnancy (Table 1), at delivery (Table
2), and at 3 months postpartum (Fig. 1)
were assessed using ANOVA for continu-
ous variables and either 
2 or Fisher’s ex-
act test for categorical variables. The
Tukey-Kramer method was used to ac-
count for multiple pairwise comparisons.
Multiple linear regression analysis was
used to identify the factors at the time of
OGTT in pregnancy that independently
predicted -cell function (log insulino-
genic index/HOMA-IR) at 3 months post-
partum. Covariates considered included
age, prepregnancy BMI, weight gain in
pregnancyprecedingtheOGTT,previous
GDM, family history of type 2 diabetes,
and glucose tolerance status in pregnancy
(with normal GCT NGT as reference
group), in addition to months postdeliv-
ery at the time of the postpartum OGTT.
Aseriesofmodelswereconstructedusing
these covariates, with the optimal model
determined by the adjusted coefﬁcient of
multiple determination R
2
a (adjusted R-
square) criterion.
RESULTS
Baseline characteristics of the study
groups
Table 1 shows the baseline characteristics
of the 361 study participants stratiﬁed
into the ﬁve glucose tolerance categories
in pregnancy, namely normal GCT NGT
(n  74), abnormal GCT NGT (n  128),
2/3-hGIGT(n34),1-hGIGT(n28),
and GDM (n  97). There were no signif-
icantdifferencesbetweenthegroupswith
Gestational impaired glucose tolerance
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parity. Women in the normal GCT NGT
groupunderwenttheOGTTinpregnancy
slightlylater(median32weeks’gestation)
than the other four groups (each median
29 weeks) (P  0.0001). As glucose tol-
erance status worsened, both personal
history of previous GDM and family his-
toryofdiabetesweremoreprevalent(P
0.0134 and P  0.0382, respectively),
and prepregnancy BMI increased (P 
0.0148). Weight gain in pregnancy pre-
ceding the OGTT was greatest in the nor-
mal GCT NGT group and lowest in the
women with 1-h GIGT and GDM (overall
P  0.0001), but weight gain per week
gestation did not differ between the
groups (P  0.2159).
The ﬁve study groups showed marked
metabolic differences in pregnancy (Table
1). Indeed, as expected, glycemic parame-
ters (GCT, fasting glucose, and AUCgluc) all
progressively increased from normal GCT
NGTtoabnormalGCTNGTto2/3-hGIGT
to 1-h GIGT to GDM (each trend P 
0.0001).Furthermore,bothISOGTT(insulin
sensitivity) and insulinogenic index/
HOMA-IR (-cell function) progressively
decreased across the groups in the same
manner(bothP0.0001),supportingear-
lier observations regarding the metabolic
heterogeneity of GIGT, wherein 1-h GIGT
resembles GDM in pregnancy.
Obstetrical outcomes of study
groups
At delivery, obstetrical outcomes were
compared between the four non-GDM
study groups (Table 2). (Women with
GDM were not included in this compari-
sonbecausetheywouldhavereceivedan-
tepartum dietary therapy with or without
Table 1—Baseline characteristics of study subjects stratiﬁed by glucose tolerance status in pregnancy
Normal
GCT NGT
Abnormal
GCT NGT 2/3-h GIGT 1-h GIGT GDM P
n 74 128 34 28 97
Age (years) 34.4  4.2 33.9  4.3 34.4  4.4 34.6  3.4 34.4  4.3 0.8975
Weeks gestation 32.0 (31.0–34.0) 29.0 (28.0–30.3) 29.0 (28.0–32.0) 29.0 (28.0–31.0) 29.0 (28.0–31.0) 0.0001
Prepregnancy BMI (kg/m
2) 22.9 (21.5–25.9) 23.8 (21.2–27.7) 23.1 (22.1–26.0) 26.6 (21.9–30.2) 25.2 (22.2–30.1) 0.0148
Weight gain in pregnancy (kg) 12.8 (10.5–16.4) 10.4 (7.7–13.6) 10.0 (8.2–14.6) 9.3 (6.8–13.6) 9.1 (5.7–13.1) 0.0001
Weight gain per week (kg/week) 0.4 (0.3–0.5) 0.3 (0.28–0.5) 0.3 (0.28–0.5) 0.4 (0.2–0.45) 0.3 (0.2–0.4) 0.2159
Smoking exposure (%) 0.1170
Never 54.1 64.8 76.5 50.0 72.2
Remote 44.6 34.4 23.5 46.4 25.8
Current 1.4 0.8 0.0 3.6 2.1
Parity (%) 0.7271
Nulliparous 62.2 45.3 55.9 50.0 52.6
1 32.4 40.6 29.4 32.1 39.2
1 5.4 14.1 14.7 17.9 8.3
Previous GDM/macrosomia (%) 0.0 4.7 8.8 14.3 8.3 0.0134
Family history of diabetes (%) 40.5 48.4 50.0 60.7 55.7 0.0382
Glucose challenge test (mmol/l) 5.7 (5.2–6.6) 8.4 (8.1–9.2) 8.4 (7.7–9.0) 8.4 (7.9–9.2) 8.8 (8.2–9.6) 0.0001
Fasting glucose (mmol/l) 4.2 (4.0–4.5) 4.4 (4.2–4.6) 4.5 (4.2–4.8) 4.8 (4.5–5.1) 4.6 (4.4–5.1) 0.0001
1-h glucose (mmol/l) 7.9 (6.9–8.6) 8.6 (7.7–9.3) 9.6 (8.9–10.1) 11.1 (10.8–11.3) 11.1 (10.8–11.8) 0.0001
2-h glucose (mmol/l) 6.6 (5.9–7.5) 7.6 (6.5–8.3) 9.0 (8.1–9.6) 8.3 (7.6–8.7) 10.1 (9.5–10.8) 0.0001
3-h glucose (mmol/l) 6.0 (5.1–6.7) 5.8 (4.6–6.8) 8.1 (7.0–8.7) 6.4 (5.2–7.1) 8.1 (6.7–9.1) 0.0001
AUCgluc 19.5  2.2 20.8  2.4 24.3  1.4 24.9  1.2 27.7  2.3 0.0001
ISOGTT 5.5 (3.6–7.5) 5.4 (3.7–7.6) 3.6 (2.8–5.2) 3.4 (2.8–4.6) 3.3 (2.3–5.2) 0.0001
Insulinogenic Index/HOMA-IR 13.2 (9.6–18.4) 12.8 (8.6–18.9) 8.2 (5.8–11.1) 5.9 (4.0–8.8) 6.3 (3.1–10.2) 0.0001
Data are median (interquartile range), mean  SD, or % unless otherwise indicated. P values refer to overall differences across the groups.
Table 2—Obstetrical outcomes per glucose tolerance group in pregnancy (excluding GDM)
Normal GCT
NGT
Abnormal
GCT NGT 2/3-h GIGT 1-h GIGT P
n 74 128 34 28
Length of gestation (weeks) 39.0 (39–40) 39.0 (38–40) 39.0 (38–40) 39.0 (38–40) 0.4608
Caesarian section (%) 30.6 34.5 45.2 51.9 0.0293
Infant sex (% male/% female) 40/60 54/46 39/61 59/41 0.2319
1 min Apgar 7 (%) 8.3 5.1 3.2 7.4 0.6061
5 min Apgar 7 (%) 0.0 0.0 3.2 0.0 0.2339
Infant birthweight (g) 3,424  480.7 3,472  572.8 3,489  542.4 3,684  501.5 0.1978
Macrosomia (%) 8.1 14.1 17.7 17.9 0.1171
LGA (%) 5.6 14.3 12.9 14.8 0.1719
Data are %, median (interquartile range), or means  SD. P values refer to overall differences across the groups.
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There were no signiﬁcant differences be-
tween the four non-GDM groups with re-
spect to length of gestation, infant sex, or
Apgar scores. The Caesarian section rate
increased across the groups from normal
GCT NGT (30.6%) to abnormal GCT
NGT (34.5%) to 2/3-h GIGT (45.2%) to
1-h GIGT (51.9%) (overall P  0.0293).
Nevertheless, although mean infant birth
weightwashighestin1-hGIGT,itdidnot
differ signiﬁcantly between the four
groups (overall P  0.1978). Further-
more, while clearly less prevalent in
women with normal GCT NGT than in
the other groups, both macrosomia and
LGA occurred with comparable fre-
quencyinthe1-hGIGT,2/3-hGIGT,and
abnormal GCT NGT groups. Finally,
upon adjustment for factors known or
suspected to inﬂuence birth weight (in-
cluding maternal age, prepregnancy BMI,
gestational weight gain, smoking status,
familyhistoryoftype2diabetes,lengthof
gestation, and infant sex), mean adjusted
birth weight did not differ signiﬁcantly
between the groups (normal GCT NGT
3,372 g, abnormal GCT NGT 3,424 g,
2/3-h GIGT 3,507 g, and 1-h GIGT 3,580
g; overall P  0.2471).
Obstetrical outcomes were also com-
pared between all ﬁve study groups (i.e.,
includingGDM).Asshowninthesupple-
mentary Table (available in an online ap-
pendix at http://dx.doi.org/10.2337/
dc07-0126), infant birth weight was
Figure 1—Glycemia, insulin sensitivity, and -cell function at 3 months
postpartumperglucosetolerancegroupinpregnancy.A:AUCgluc,trendP
0.0001;GDMvs.normalGCTNGT,P0.0001;1-hGIGTvs.normalGCT
NGT, P  0.0002; 2/3-h GIGT vs. normal GCT NGT, P  0.0012; abnor-
malGCTNGTvs.normalGCTNGT,P0.0581;GDMvs.abnormalGCT
NGT, P  0.0001; and 1-h GIGT vs. abnormal GCT NGT, P  0.0551. B:
ISOGTT, trend P  0.002; GDM vs. normal GCT NGT, P  0.0217; and 1-h
GIGTvs.normalGCTNGT,P0.0212.C:Insulinogenicindex/HOMA-IR,
trend P  0.0001; GDM vs. normal GCT NGT, P  0.0001; 1-h GIGT vs.
normalGCTNGT,P0.0001;GDMvs.abnormalGCTNGT,P0.0179;
and 1-h GIGT vs. abnormal GCT NGT, P  0.0178. (For each box-and-
whiskerplot:lineinsideboxindicatesmedian,upperandlowerlimitsofbox
indicate75thand25thpercentiles,upperandlowerbarsindicatemaximum
and minimum values, and plus sign indicates mean.)
Gestational impaired glucose tolerance
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groups (overall P  0.0009) (in contrast
to the comparison of the four non-GDM
groups in Table 2). This result was due to
the signiﬁcantly lower birth weight in
women with GDM (mean 3,256  452.2
g), particularly in comparison to those
with 1-h GIGT (mean 3,684  501.5 g)
(pairwiseP0.0002).RatesofCaesarian
section and LGA were also lower in the
GDM than in the 1-h GIGT group, but
these differences did not reach statistical
signiﬁcance (supplementary Table).
Postpartum characteristics of study
groups
At the 3-month postpartum OGTT, there
were no signiﬁcant differences between
theoriginalﬁvestudygroupswithrespect
to months since delivery, blood pressure,
low rates of current smoking, and high
rates of breastfeeding (data not shown).
Waist circumference increased across the
groups from normal GCT NGT (median
[interquartile range]) (85.5 cm [79.8–
85.0]) to abnormal GCT NGT (85.4
[79.2–94.2]) to 2/3-h GIGT (88.5 [84.0–
97.0]) to 1-h GIGT (90.1 [83.7–103.8])
to GDM (89.7 [81.0–98.5]) (P 
0.0359). Current BMI showed a similar
patternbutdidnotreachstatisticalsignif-
icance in the normal GCT NGT (24.4
kg/m
2[22.6–27.9]),abnormalGCTNGT
(25.9 [23.5–30.2]), 2/3-h GIGT (26.1
[22.8–30.2]), 1-h GIGT (26.9 [25.0–
31.5]), and GDM (26.9 [23.4–31.1])
groups (P  0.1203). In total, 54 women
had abnormal OGTT results at 3 months
postpartum.
Importantly, the metabolic differ-
ences between the ﬁve groups that were
observed in pregnancy persisted at 3
months postpartum. Indeed, AUCgluc
progressively increased across the groups
from normal GCT NGT to abnormal GCT
NGT to 2/3-h GIGT to 1/h GIGT to GDM
(trend P  0.0001) (Fig. 1A). Insulin re-
sistance followed the same progression,
with ISOGTT decreasing across the groups
(trend P  0.002) (Fig. 1B). Of note, for
insulin sensitivity, the only between-
group comparisons that reached statisti-
cal signiﬁcance were between 1) GDM
and normal GCT NGT (pairwise P 
0.0217) and 2) 1-h GIGT and normal
GCT NGT (pairwiseP  0.0212). In con-
trast to the modest differences in insulin
sensitivity,thevariationin-cellfunction
between the ﬁve study groups was much
more profound. As shown in Fig. 1C, in-
sulinogenic index/HOMA-IR progres-
sively decreased from normal GCT NGT
to abnormal GCT NGT to 2/3-h GIGT to
1/h GIGT to GDM (trend P  0.0001).
Furthermore, the GDM and 1-h GIGT
groups, in particular, both exhibited
markedly decreased -cell function, as
evidenced by signiﬁcant pairwise com-
parisons with both normal GCT NGT
(P0.0001forGDMandP0.0001for
1-h GIGT) and abnormal GCT NGT (P 
0.0179 for GDM and P  0.0178 for 1-h
GIGT).
Having thus established that GDM
and 1-h GIGT are associated with greater
postpartumglycemiathantheotherstudy
groups and that this glycemia is likely at-
tributable to marked differences in -cell
function (rather than more modest differ-
ences in insulin sensitivity), we sought to
determine whether these two glucose tol-
erance groups in pregnancy indepen-
dently predict postpartum -cell
dysfunction. On multiple linear regres-
sion analysis, the strongest independent
and negative predictors of dependent
variable log insulinogenic index/
HOMA-IR at 3 months postpartum were
indeed GDM (t  4.14, P  0.0001)
and 1-h GIGT (t  3.79, P  0.0002).
Other weaker independent predictors
were a history of GDM in a prior preg-
nancy (t  2.94, P  0.0035), 2/3-h
GIGT in the current pregnancy (t 
2.22, P  0.0273), and abnormal GCT
NGT (t  1.98, P  0.0483). These
predictors were not signiﬁcantly changed
when the regression analysis was rerun
with the exclusion of a single extreme ob-
servation (insulinogenic index/HOMA-IR
138 at 3 months postpartum in subject
from the abnormal GCT NGT group).
CONCLUSIONS— Inthisreport,we
demonstrate that in women with GIGT,
the timing of the single abnormal glucose
value on antepartum OGTT has implica-
tions for metabolic function both in preg-
nancy and postpartum. Speciﬁcally, in
contrast to 2/3-h GIGT, 1-h GIGT bears
metabolic resemblance to GDM in preg-
nancy. Furthermore, this similarity with
GDM extends to the postpartum, where
1-h GIGT remains associated with in-
creased glycemia, insulin resistance, and
-cell dysfunction. Indeed, its indepen-
dent association with -cell dysfunction,
in particular, suggests that 1-h GIGT, like
GDM, may predict an increased future
risk of type 2 diabetes, an important pos-
sibility that warrants further study.
The concept that GIGT is a metabol-
ically heterogeneous disorder originally
arosefromourobservationthat1-hGIGT
and GDM were both characterized by
greater glycemia, higher insulin resis-
tance, and lower circulating levels of the
insulin-sensitizing protein adiponectin
than 2/3-h GIGT and NGT in pregnancy
(8). Di Cianni et al. (7) subsequently re-
ported that 1-h GIGT was also associated
with poorer -cell function in pregnancy
(measured by insulin secretion sensitivity
index) than 2/3-h GIGT. In this context,
the current study conﬁrms the idea that
1-hGIGTrepresentsthemoreseveremet-
abolic perturbation in pregnancy, charac-
terized by greater glycemia, lower insulin
sensitivity, and markedly reduced -cell
function (measured by insulinogenic in-
dex/HOMA-IR). From a clinical perspec-
tive, however, the key question is in fact
whether 1-h GIGT is associated with the
same adverse outcomes as GDM, speciﬁ-
cally increased infant birth weight and
postpartum metabolic dysfunction. The
current study was thus designed to ad-
dress these important issues.
Our ﬁndings clearly demonstrate
that, like GDM, 1-h GIGT is associated
with signiﬁcant metabolic dysfunction at
3 months postpartum, including in-
creased glycemia (AUCgluc), greater insu-
lin resistance, and poorer -cell function.
Furthermore, while the differences be-
tween the study groups in insulin sensi-
tivity were more modest, the variation in
-cell function at 3 months postpartum
was profound, with insulinogenic index/
HOMA-IR markedly reduced in women
with 1-h GIGT and GDM compared with
their peers (Fig. 1C). Indeed, on multiple
linear regression analysis, GDM and 1-h
GIGT emerged as the strongest indepen-
dent negative predictors of postpartum
-cell function. When one considers that
-cell dysfunction is believed to underlie
the considerable risk of type 2 diabetes in
women with GDM (2,17) and that it has
recently emerged as the strongest meta-
bolic predictor of progression to type 2
diabetes in a longitudinal study of 2,115
nondiabetic individuals followed over 6
years (18), the current ﬁndings raise the
important possibility that women with
1-h GIGT may face an increased future
risk of type 2 diabetes. If 1-h GIGT iden-
tiﬁes a high-risk patient population, then
postpartum screening for type 2 diabetes,
akin to that which is currently recom-
mended for GDM, would be indicated.
Clearly, this issue demands further study,
including long-term follow-up to deter-
mine the risk of type 2 diabetes and ap-
propriate cost-beneﬁt evaluation of
postpartum care strategies.
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demonstrate that 1-h GIGT resembles
GDMinpredictingpostpartummetabolic
dysfunction, the obstetrical implications
of this condition are not certain. Several
studies have linked GIGT (without dis-
tinction between 1-h vs. 2/3-h) with an
increased risk of adverse obstetrical out-
comes related to fetal overgrowth (19–
24).Consideringthat1-hGIGTandGDM
share a similar metabolic phenotype and
that hyperglycemia at 1-h on OGTT has
been associated with an increased likeli-
hood of fetal hyperinsulinemia (25,26), it
is reasonable to anticipate that 1-h GIGT,
inparticular,maypredictincreasedinfant
birth weight. Nevertheless, in the current
study,althoughtheCaesariansectionrate
was highest in the 1-h GIGT group, there
were no signiﬁcant differences between
thefournon-GDMgroupsinmacrosomia
or delivery of an LGA infant. Further-
more, while both unadjusted and ad-
justed birth weight were highest in the
women with 1-h GIGT, neither result
reachedstatisticalsigniﬁcanceincompar-
ison across the groups. At present, a few
potential explanations may be considered
inrelationtotheseobservations.First,if
1-h GIGT is truly associated with in-
creased birth weight, then perhaps the
current study was underpowered to de-
tect this relationship. Indeed, since sev-
eral factors are known to impact infant
birth weight, including, most notably,
maternal overweight/obesity (27,28), a
large sample size may be required for
detection of an otherwise modest effect.
Alternatively, it is possible that 1-h
GIGT does not mimic GDM in affecting
birth weight. In that case, 1-h GIGT
may provide insight into the physiology
ofGDMcomplicationsbyseparatingthe
risk of fetal overgrowth (i.e., which 1-h
GIGT does not carry) from the risk of
postpartum metabolic dysfunction,
which GDM and 1-h GIGT both share.
In any event, further study of this issue
is warranted.
A limitation of the current analysis is
the relatively modest number of women
withGIGTinthestudy.Nevertheless,itis
encouraging that consistent relationships
between GIGT subgroups and glycemia,
insulin sensitivity, and -cell function
were readily apparent both in pregnancy
and at 3 months postpartum, despite the
sample size (partly speaking to the
strength of these associations). Moreover,
this study represents, to our knowledge,
the ﬁrst investigation of the speciﬁc effect
of 1-h GIGT on obstetrical outcomes and
postpartum metabolic function and
should lead to further studies.
In summary, the metabolic similarity
between 1-h GIGT and GDM extends to
thepostpartumperiod.Indeed,bothcon-
ditions are associated with increased gly-
cemia, insulin resistance, and -cell
dysfunction both in pregnancy and at 3
months postpartum. Furthermore, its
independent association with -cell
dysfunction, in particular, suggests that
1-h GIGT, like GDM, may predict an
increased future risk of type 2 diabetes
and hence may identify a high-risk pa-
tient population that warrants postpar-
tum surveillance.
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